Has Richard Frame received payments from drug or device companies?

Yes. Drug and device makers reported $1,744 in general payments to Richard Frame across 38 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Richard Frame did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Richard Frame come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Richard Frame

Medical Oncology · Salt Lake City, UTNPI 1073563516

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,290 of the $1,744 with a category attached, or 74.0%. 22 manufacturers reported payments, led by Daiichi Sankyo Inc. at 33.8% of the total. Reporting peaked in 2020 at $828 and has fallen 84.5% since, to $128 in 2025. That places this record below the midpoint for medical oncology clinicians in UT, where the typical reported total is $2,800.

$1,744in general payments, 2019–2025

Across 38 payments — averaging $45.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Daiichi Sankyo Inc.$590
AstraZeneca$243
Incyte Corporation$129
Johnson & Johnson$127
Rigel Pharmaceuticals, Inc.$111
Foundation Medicine, Inc.$97
plus $446 from 16 others

What the payments were for

Consulting fees$40023%
Food & beverage$1,29074%
Education$533%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Daiichi Sankyo Inc.	8	$590
AstraZeneca	2	$243
Incyte Corporation	1	$129
Johnson & Johnson	2	$127
Rigel Pharmaceuticals, Inc.	1	$111
Foundation Medicine, Inc.	1	$97
AbbVie	2	$59
E.r. Squibb & Sons, L.L.C.	1	$52
Eisai Inc.	2	$39
Merck	2	$38
Lilly USA, LLC	2	$37
Jazz Pharmaceuticals Inc.	2	$37
Coherus Oncology, Inc.	2	$36
Regeneron Healthcare Solutions, Inc.	1	$25
Clovis Oncology, Inc.	2	$20
EMD Serono, Inc.	1	$19
Puma Biotechnology, Inc.	1	$17
Astellas Pharma US Inc	1	$15
Seagen Inc.	1	$15
Pfizer	1	$13
Gilead	1	$12
Sanofi	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,744 in reported general payments places this provider in the 40th percentile of 43 medical oncology providers in Utah.

See all medical oncology providers in Utah →

Other medical oncology in Salt Lake City

Bradley HunterSalt Lake City$263K
Robert HavardSalt Lake City$57K
Wallace AkerleySalt Lake City$38K
Ignacio Garrido-LagunaSalt Lake City$35K
Mei WeiSalt Lake City$34K
Xylina GreggSalt Lake City$31K
Paul ShamiSalt Lake City$28K
Nitin ChandramouliSalt Lake City$19K
Kenneth GrossmannSalt Lake City$15K
Manish KohliSalt Lake City$13K

See the full list for Utah →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →